Influenza virus vaccine transdermal - Valneva USA

Drug Profile

Influenza virus vaccine transdermal - Valneva USA

Alternative Names: Influenza vaccine transdermal - Valneva USA; Needle-free influenza patch - Valneva USA

Latest Information Update: 12 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Iomai Corporation
  • Developer Intercell USA
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Influenza virus infections

Most Recent Events

  • 11 Dec 2017 Intercell USA is now called Valneva USA
  • 29 May 2007 Clinical data added to the adverse events and Viral Infections immunogenicity sections
  • 17 Jan 2007 Iomai awarded US Department of Health and Human Services contract for the development of a dose-sparing patch for use with a pandemic influenza vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top